Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
73.28
-0.54 (-0.74%)
At close: Jun 12, 2026, 4:00 PM EDT
73.75
+0.47 (0.65%)
After-hours: Jun 12, 2026, 6:39 PM EDT
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
TRYNGOLZA Revenue | 128.30M | 107.50M | - | ||||||||||||
TRYNGOLZA Revenue Growth | 19.35% | - | - | ||||||||||||
DAWNZERA Revenue | - | 7.80M | - | ||||||||||||
Total Product Revenue | 152.00M | 115.30M | - | ||||||||||||
Total Product Revenue Growth | 31.83% | - | - | ||||||||||||
SPINRAZA Royalties Revenue | 208.00M | 212.30M | 216.10M | ||||||||||||
SPINRAZA Royalties Revenue Growth | -2.02% | -1.76% | -10.11% | ||||||||||||
WAINUA Royalties Revenue | 50.40M | 49.10M | 20.20M | ||||||||||||
WAINUA Royalties Revenue Growth | 2.65% | 143.07% | - | ||||||||||||
TEGSEDI and WAYLIVRA Revenue | 32.10M | 35.00M | 34.20M | ||||||||||||
TEGSEDI and WAYLIVRA Revenue Growth | -8.29% | 2.34% | -2.01% | ||||||||||||
Commercial Licensing and Other Royalty Revenue | 18.60M | 24.10M | 22.60M | ||||||||||||
Commercial Licensing and Other Royalty Revenue Growth | -22.82% | 6.64% | -32.13% | ||||||||||||
Total Commercial Revenue | 467.40M | 435.80M | 293.10M | ||||||||||||
Total Commercial Revenue Growth | 7.25% | 48.69% | -5.02% | ||||||||||||
Amortization from Upfront Payments Revenue | - | - | 131.40M | ||||||||||||
Amortization from Upfront Payments Revenue Growth | - | - | 4.87% | ||||||||||||
Milestone Payments Revenue | - | - | 106.40M | ||||||||||||
Milestone Payments Revenue Growth | - | - | 5.87% | ||||||||||||
R&D License Fees Revenue | - | - | 71.30M | ||||||||||||
R&D License Fees Revenue Growth | - | - | -38.95% | ||||||||||||
Other R&D Services Revenue | - | - | 23.50M | ||||||||||||
Other R&D Services Revenue Growth | - | - | 135.00% | ||||||||||||
Collaborative Agreement Revenue | 541.50M | 465.80M | 332.60M | ||||||||||||
Collaborative Agreement Revenue Growth | 16.25% | 40.05% | -5.67% | ||||||||||||
Eplontersen Joint Development Revenue | 49.30M | 42.10M | 79.40M | ||||||||||||
Eplontersen Joint Development Revenue Growth | 17.10% | -46.98% | -37.18% | ||||||||||||
Total R&D Revenue | 590.80M | 507.90M | 412.00M | ||||||||||||
Total R&D Revenue Growth | 16.32% | 23.28% | -13.99% | ||||||||||||
Revenue (Other) | -793.21M | -672.29M | -432.16M | ||||||||||||
Revenue (Total) | 1.06B | 943.71M | 705.14M | ||||||||||||
Revenue (Total) Growth | 12.13% | 33.83% | -10.47% |